Swiss startup PeakData picks up €12.1 million for its platform connecting pharma companies with healthcare professionals
-
Loading... - harvey sophie
- 01 Sep 2022
- 72 Views
- 0 Like
- 0 Comment
Getting new treatments and medicines to patients requires many steps in the chain. One of the critical parts is bridging a connection between the pharmaceutical companies creating the treatments, and the HCPs that can deliver them to patients.
Aiming to enhance the process, Zug-based PeakData has developed an AI web-based platform that offers HCP insights for global pharmaceutical companies. The Swiss startup has now secured €12.1 million in fresh funding.
Series A Funding
AlbionVC led the Series A funding with Octopus Ventures and Heal Capital also participating.
It follows a year of rapid growth – PeakData has reported 6x growth in 2021 and is now being used by over half of Europe’s largest pharma companies. It’s resultingly grown its employee headcount from 12-70 over the past year.
The Swiss startup will use the funding to expand all aspects of the business to support its growth plans as well as continue to develop the platform. The company aims to have its platform used by the vast majority of pharmaceutical companies around the globe and in as many drug markets as possible in the next five years.
AI Customer targeting platform for healthcare
Launched in 2018, PeakData enables pharmaceutical companies to enhance the depth and breadth of their customer base and learn more about HCPs that are most relevant to their target market. The platform uses AI algorithms to rank these HCPs in terms of their digital impact, influence and relevance to their target market. It uses dynamic data to observe changes in HCP status over time.
It means that not only can pharma companies find and personalise their communications with the top-tier experts, as the market changes, but the platform also enables them to identify emerging influencers among local treating physicians who are managing patients daily who may previously not have been on their radar. Read More…
